Skip to main
LENZ

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics Inc. has demonstrated strong potential for growth, having completed a comprehensive clinical program consisting of three Phase 3 trials (CLARITY program) that showcased both strong efficacy and a favorable safety profile, positioning the company for a leading market presence in the treatment of presbyopia. Additionally, projections indicate that LENZ could achieve profitability by 2028, a key milestone that would enhance its financial stability and investor confidence. As a strategic response to the positive trial outcomes, the company plans to expand its sales force, which should further bolster revenue growth and market penetration.

Bears say

LENZ Therapeutics, Inc. faces significant commercial challenges in changing long-standing consumer behaviors regarding presbyopia treatment, which could hinder market adoption of its lead product, Vizz. The lack of a diverse pipeline beyond Vizz raises concerns about the company's ability to sustain growth and leverage its commercial infrastructure effectively. Additionally, the competitive landscape includes other treatments for presbyopia, and potential challenges to Vizz’s intellectual property may necessitate further funding or strategic partnerships, adding to the uncertainty around the company's financial stability and future prospects.

LENZ has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 4 analysts, LENZ has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.